Skip to content

US · ARQT · BIOTECHNOLOGY

Arcutis Biotherapeutics, Inc. (ARQT) intrinsic value and stock valuation

$26.36as of 2026-11-21 · Mkt cap 3.39B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Arcutis Biotherapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ARQT with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from ARQT’s statements →

Arcutis Biotherapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Westlake Village, CA 91361 arcutis.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$376.1M
20172025
Net income
-$-16.14M
20172025
Free cash flow
-$-6.31M
20172025
Total equity
$189.5M-6.9% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$376.1M$196.5M$59.6M$3.69M$0.00
Operating income-$-12.23M-$-128.4M-$-241.1M-$-301.63M-$-206.53M
Net income-$-16.14M-$-140.04M-$-262.14M-$-311.46M-$-206.36M
EPSd-$-126.86K-$-1.16M-$-3.78M-$-5.66M-$-4.18M
Operating cash flow-$-5.62M-$-112.16M-$-247.06M-$-257.71M-$-174.63M
Capital expenditure-$-690K-$-140K-$-430K-$-23.28M-$-990K
Free cash flow-$-6.31M-$-112.3M-$-247.49M-$-281M-$-175.62M
Total assets$433M$348.9M$341.4M$449.3M$408.2M
Total debt$6.27M$110.6M$205.9M$202.5M$77.6M
Net debt-$-36.64M$39.3M$117.5M$148.9M-$-20.43M
Total equity$189.5M$157.5M$88.7M$209.6M$297.7M
Cash and short-term investments$221M$228M$271.9M$409.6M$388.6M
Income statement
20252024202320222021
Revenue$376.1M$196.5M$59.6M$3.69M$0.00
Cost of revenue$36.7M$19.1M$4.99M$750K$760K
Gross profit$339.4M$177.4M$54.6M$2.93M-$-760K
Research and development expenses$77.1M$76.4M$110.6M$182.4M$145.6M
Selling, general and administrative expenses$274.6M$229.4M$185.2M$122.1M$61M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$351.6M$305.8M$295.7M$304.6M$205.8M
Cost and expenses$388.3M$324.9M$300.7M$305.3M$206.5M
Interest income$0.00$0.00$0.00$0.00$170K
Interest expense$12.1M$27.2M$29.7M$15.7M$0.00
Depreciation and amortization$5.37M$2.6M$1.88M$1.25M$760K
Ebitda$2.48M-$-109.62M-$-227.43M-$-294.55M-$-205.59M
Operating income-$-12.23M-$-128.4M-$-241.1M-$-301.63M-$-206.53M
Total other income/expenses, net-$-2.74M-$-10.99M-$-17.93M-$-9.83M$170K
Income before tax-$-14.97M-$-139.39M-$-259.03M-$-311.46M-$-206.36M
Income tax expense$1.17M$650K$3.11M$0.00$0.00
Net income-$-16.14M-$-140.04M-$-262.14M-$-311.46M-$-206.36M
Weighted average shares outstanding$127.2M$121M$69.3M$55M$49.4M
Weighted average diluted shares outstanding$127.2M$121M$69.3M$55M$49.4M
Balance sheet
20252024202320222021
Cash and short-term investments$221M$228M$271.9M$409.6M$388.6M
Net receivables$146.2M$73.1M$25.8M$8.46M$360K
Inventory$22.6M$14.5M$13.1M$7.51M$0.00
Total current assets$411.2M$335.8M$330.4M$437.4M$402.8M
Property, plant and equipment, net$5.51M$2.99M$3.9M$4.6M$5.3M
Goodwill and intangible assets$14.8M$9.48M$6.44M$7.19M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$21.7M$13.1M$10.9M$11.9M$5.38M
Total assets$433M$348.9M$341.4M$449.3M$408.2M
Accounts payable$12.5M$14.2M$12M$8.83M$7.35M
Short-term debt$1M$820K$730K$1.31M$430K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$129.8M$81M$46.7M$37.8M$33.3M
Long-term debt$5.27M$109.8M$205.2M$201.9M$77.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$113.7M$110.3M$206M$201.9M$77.2M
Capital lease obligations$0.00$3.38M$4.12M$4.77M$4.77M
Total liabilities$243.5M$191.4M$252.7M$239.7M$110.5M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.14B-$-1.12B-$-981.9M-$-719.76M-$-408.31M
Accumulated other comprehensive income (loss)-$-40K-$-10K$0.00-$-1.09M-$-260K
Total equity$189.5M$157.5M$88.7M$209.6M$297.7M
Total investments$178.1M$156.6M$183.5M$356M$290.6M
Total debt$6.27M$110.6M$205.9M$202.5M$77.6M
Net debt-$-36.64M$39.3M$117.5M$148.9M-$-20.43M
Cash flow statement
20252024202320222021
Net income-$-16.14M-$-140.04M-$-262.14M-$-311.46M-$-206.36M
Depreciation and amortization$4.67M$2.6M$1.52M$930K$450K
Stock-based compensation$40.4M$41.7M$38.8M$32.7M$23.9M
Change in working capital-$-34.83M-$-15.08M-$-23.5M-$-10.18M$3.62M
Accounts receivable-$-73.16M-$-47.26M-$-17.35M-$-8.46M$0.00
Inventory-$-7.33M-$-400K-$-5.62M-$-7.51M$0.00
Accounts payable-$-1.69M$2.23M$3.15M$1.56M$240K
Net cash provided by operating activities-$-5.62M-$-112.16M-$-247.06M-$-257.71M-$-174.63M
Investments in property, plant and equipment-$-690K-$-140K-$-430K-$-23.28M-$-990K
Acquisitions, net$0.00$0.00$0.00$23M$75M
Net cash used for investing activities-$-30.25M$28.8M$180.2M-$-87.2M-$-75.95M
Common stock issued$6.97M$161.7M$98.9M$176.1M$207.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.97M$66.2M$101.3M$301.8M$282M
Net change in cash-$-28.74M-$-17.37M$34.5M-$-43.12M$31.4M
Cash at end of period$43.2M$72M$89.3M$54.9M$98M
Operating cash flow-$-5.62M-$-112.16M-$-247.06M-$-257.71M-$-174.63M
Capital expenditure-$-690K-$-140K-$-430K-$-23.28M-$-990K
Free cash flow-$-6.31M-$-112.3M-$-247.49M-$-281M-$-175.62M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Arcutis Biotherapeutics, Inc.

        Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

        CEO
        Todd Franklin Watanabe
        Employees
        354
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Arcutis Biotherapeutics, Inc. (ARQT)?

        Arcutis Biotherapeutics, Inc. (ARQT) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ARQT undervalued?

        ARQT trades at a price of $26.36 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.